Product Datasheet

p107 Antibody - BSA Free
NBP2-33735

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-33735

Updated 12/2/2025 v.20.1



NBP2-33735

p107 Antibody - BSA Free

Product Information	
Unit Size	0.1 ml
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS (pH 7.2) and 40% Glycerol

Product Description	
Description	Novus Biologicals Rabbit p107 Antibody - BSA Free (NBP2-33735) is a polyclonal antibody validated for use in IHC, WB and ICC/IF. Anti-p107 Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	5933
Gene Symbol	RBL1
Species	Human
Reactivity Notes	Immunogen displays the following percentage of sequence identity for non-tested species: Mouse (86%), Rat (86%)
Immunogen	This antibody was developed against a recombinant protein corresponding to amino acids: ESLAWSHDSALWEALQVSANKVPTCEEVIFPNNFETGNGGNVQGHLPLMPMS PLMHPRVKEVRTDSGSLRRDMQPLSPISVHER

Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 0.04-0.4 ug/ml, Immunohistochemistry 1:200 - 1:500, Immunocytochemistry/ Immunofluorescence 0.25-2 ug/ml, Immunohistochemistry-Paraffin 1:200 - 1:500
Application Notes	For IHC-Paraffin, HIER pH 6 retrieval is recommended. ICC/IF Fixation Permeabilization: Use PFA/Triton X-100.

Images

Immunohistochemistry-Paraffin: p107 Antibody [NBP2-33735] - Staining of human colon, kidney, liver and testis using Anti-p107 antibody NBP2-33735 (A) shows similar protein distribution across tissues to independent antibody NBP2-33791 (B).	
Western Blot: p107 Antibody [NBP2-33735] - Lane 1: Marker [kDa] 250, 130, 95, 72, 55, 36, 28, 17, 10. Lane 2: Human cell line RT-4. Lane 3: Human cell line U-251MG sp	
Immunocytochemistry/Immunofluorescence: p107 Antibody [NBP2-33735] - Selinexor alters pocket protein expression in nuclear and cytoplasmic compartments. Representative images of p107, p130 and RB (green) IF staining of bladder cancer cells treated with vehicle (V) or selinexor (S) for 48 hours. Tubulin staining (red) and DAPI staining (blue) served to define the cytoplasmic and nuclear compartments, respectively. The inserts are magnifications of the boxed cells. Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/fulltext/26179), licensed under a CC-BY license.	
Immunocytochemistry/Immunofluorescence: p107 Antibody [NBP2-33735] - Immunofluorescent staining of human cell line HeLa shows localization to nucleoplasm.	

Immunohistochemistry-Paraffin: p107 Antibody [NBP2-33735] - Staining of human testis shows moderate nuclear postivity in cells in seminiferous ducts and Leydig cells.	
Immunohistochemistry-Paraffin: p107 Antibody [NBP2-33735] - Staining of human colon shows moderate nuclear positivity in glanular cells.	
Immunohistochemistry-Paraffin: p107 Antibody [NBP2-33735] - Staining of human kidney shows moderate nuclear postivity in cells in tubules.	
Immunohistochemistry-Paraffin: p107 Antibody [NBP2-33735] - Staining of human liver shows no positivity in hepatocytes as expected.	

Western Blot: p107 Antibody [NBP2-33735] - Selinexor alters pocket protein expression in nuclear & cytoplasmic compartments(A) Representative images of p107, p130 & RB (green) IF staining of bladder cancer cells treated with vehicle (V) or selinexor (S) for 48 hours. Tubulin staining (red) & DAPI staining (blue) served to define the cytoplasmic & nuclear compartments, respectively. The inserts are magnifications of the boxed cells. (B) Quantification of staining intensity of pocket proteins normalized to DAPI. (C) Nuclear & cytoplasmic fractions of cell treated with vehicle or 0.15 uM selinexor (UM-UC-3 & T24 cells), 0.25 uM selinexor (J82) & 0.5 uM selinexor (TCCSUP) for 72 hours were assessed for the expression of RB, p107 & p130. Nup62 & tubulin were used as markers for the nuclear & cytoplasmic fractions, respectively. (D) T24 & UM-UC-3 cells transfected with siC or siRB & were treated with vehicle or 0.1 uM selinexor for 72 hours. The results are shown as percent cell viability comparing drug treated to vehicle treated cells. (E) Palbociclib reduces T24 & UM-UC-3 bladder tumor cells viability in a dose dependent manner. (F) Combined selinexor (0.1 uM) & palbociclib (0.5 uM) treatment is more effective in reducing viability of cells than either treatment alone where the CI = 1.04 for UM-UC-3 cells & 1.02 for T24 cells indicating an additive response. Error bars = ± standard deviation. Student's t test; * denotes p ≤ 0.05, ** denotes p ≤ 0.01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30349650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Immunocytochemistry/ Immunofluorescence: p107 Antibody [NBP2-33735] - Selinexor alters pocket protein expression in nuclear & cytoplasmic compartments(A) Representative images of p107, p130 & RB (green) IF staining of bladder cancer cells treated with vehicle (V) or selinexor (S) for 48 hours. Tubulin staining (red) & DAPI staining (blue) served to define the cytoplasmic & nuclear compartments, respectively. The inserts are magnifications of the boxed cells. (B) Quantification of staining intensity of pocket proteins normalized to DAPI. (C) Nuclear & cytoplasmic fractions of cell treated with vehicle or 0.15 uM selinexor (UM-UC-3 & T24 cells), 0.25 uM selinexor (J82) & 0.5 uM selinexor (TCCSUP) for 72 hours were assessed for the expression of RB, p107 & p130. Nup62 & tubulin were used as markers for the nuclear & cytoplasmic fractions, respectively. (D) T24 & UM-UC-3 cells transfected with siC or siRB & were treated with vehicle or 0.1 uM selinexor for 72 hours. The results are shown as percent cell viability comparing drug treated to vehicle treated cells. (E) Palbociclib reduces T24 & UM-UC-3 bladder tumor cells viability in a dose dependent manner. (F) Combined selinexor (0.1 uM) & palbociclib (0.5 uM) treatment is more effective in reducing viability of cells than either treatment alone where the CI = 1.04 for UM-UC-3 cells & 1.02 for T24 cells indicating an additive response. Error bars = ± standard deviation. Student's t test; * denotes p ≤ 0.05, ** denotes p ≤ 0.01. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30349650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Baek HB, Lombard AP, Libertini SJ et al. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget. 2018-10-02 [PMID: 30349650] (WB, ICC/IF, Human)

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-33735

NBP2-33735PEP	p107 Recombinant Protein Antigen
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-33735

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications